Wellington Capital Management’s AbbVie ABBV Stock Holding History

Wellington Capital Management’s Portfolio ABBV Stock Details ABBV Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q2	$573K	Buy	+3,853	New	+$716K	0.86%	54

Other funds holding ABBV

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Charles Schwab San Francisco, California $654B AUM 26.35% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Norges Bank Oslo, Norway $935B AUM

Wellington Capital Management's ABBV Position: Q2 2025 in Review

Wellington Capital Management opened a new position in AbbVie (ABBV) in Q2 2025: 3,853 shares worth $573K. The stake represents 0.86% of the portfolio and ranks #54 among its holdings.

3,780 funds tracked by Wall St. Rank hold ABBV as of Q2 2025.

Wellington Capital Management held 3,853 shares of AbbVie worth $573K as of Q2 2025.
AbbVie was a new Wellington Capital Management position in Q2 2025.
AbbVie made up 0.86% of Wellington Capital Management's portfolio in Q2 2025, its #54 holding.
3,780 funds tracked by Wall St. Rank held AbbVie as of Q2 2025.

Based on Wellington Capital Management's 13F filing for Q2 2025, filed 18 Aug 2025.